Scarica l'app Stockscreener
21.43
2.68%
0.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$20.87
Aprire:
$20.89
Volume 24 ore:
2.24M
Relative Volume:
0.59
Capitalizzazione di mercato:
$15.92B
Reddito:
$956.00K
Utile/perdita netta:
$-221.32M
Rapporto P/E:
-66.97
EPS:
-0.32
Flusso di cassa netto:
$-142.25M
1 W Prestazione:
+2.29%
1M Prestazione:
-8.89%
6M Prestazione:
+13.33%
1 anno Prestazione:
+15.15%
Intervallo 1D:
$20.48
$21.49
Intervallo di 1 settimana:
$20.29
$22.21
Portata 52W:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
21.43 | 15.50B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - WV News
How to use Fibonacci retracement on Summit Therapeutics Inc.Take Profit & Daily Profit Focused Stock Screening - newser.com
How the European Spotlight on Ivonescimab’s Phase III Data Could Shape Summit Therapeutics (SMMT) - simplywall.st
How to monitor Summit Therapeutics Inc. with trend dashboards2025 Historical Comparison & Risk Controlled Stock Pick Alerts - newser.com
Is Summit Therapeutics Inc. forming a bottoming baseJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Is Summit Therapeutics Inc. stock supported by strong cash flowsRisk Management & Safe Entry Zone Identification - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation - Yahoo Finance
H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones - MSN
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence - Benzinga
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - Yahoo Finance
Will Summit Therapeutics Inc. stock continue dividend increasesJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Published on: 2025-09-30 03:00:28 - newser.com
Published on: 2025-09-30 00:09:58 - newser.com
Will Summit Therapeutics Inc. stock gain from lower inflationWeekly Profit Recap & Pattern Based Trade Signal System - newser.com
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What analysts say about Summit Therapeutics Inc stockResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
Summit Therapeutics Inc Stock Analysis and ForecastAI-Driven Market Analysis & Learn From the Strategies of Institutions - earlytimes.in
Positive Catalyst Watch Boosts SMMT Stock Outlook - GuruFocus
Barclays Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Maintains Target Price $13 - 富途牛牛
Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
First-Ever PD-1 Therapy Superiority: Summit's Ivonescimab Achieves Breakthrough in Advanced Lung Cancer Trial - Stock Titan
Weekly Analysts’ Ratings Updates for Summit Therapeutics (SMMT) - Defense World
Voya Investment Management LLC Sells 34,041 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC $SMMT Shares Sold by Wealth Management Partners LLC - MarketBeat
Barclays Begins Coverage on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics Inc. stock chart pattern explainedWeekly Profit Recap & Accurate Intraday Trade Tips - newser.com
Summit Therapeutics Inc. (SMMT) Stock Analysis: Assessing a 73% Potential Upside Amidst Clinical Innovations - DirectorsTalk Interviews
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Barclays - MarketBeat
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China - MSN
Will Summit Therapeutics Inc. benefit from macro trendsJuly 2025 Fed Impact & High Conviction Investment Ideas - newser.com
Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright - MarketBeat
Aug Catalysts: Is Summit Therapeutics Inc benefiting from innovation trendsTrade Entry Summary & Reliable Price Breakout Signals - خودرو بانک
Breakout Watch: Is Summit Therapeutics Inc vulnerable to short sellersJuly 2025 Review & Fast Gain Stock Trading Tips - خودرو بانک
Voya Investment Management LLC Lowers Stock Position in Summit Therapeutics PLC $SMMT - Defense World
Is a relief rally coming for Summit Therapeutics Inc. holdersMarket Sentiment Report & Community Trade Idea Sharing Platform - newser.com
Real time alert setup for Summit Therapeutics Inc. performanceStop Loss & Stepwise Trade Signal Implementation - newser.com
Institution Moves: Is CMND stock heavily shorted2025 Earnings Surprises & Consistent Return Investment Signals - khodrobank.com
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):